First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
PurposePanitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated first-line panitumumab plus FOLFIRI in patients with mCRC.MethodsIn this phase II, single-arm study, panitumumab (6 mg/kg) and FOLFIRI...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Journal of cancer research and clinical oncology
Year: 2011, Jahrgang: 138, Heft: 1, Pages: 65-72 |
| ISSN: | 1432-1335 |
| DOI: | 10.1007/s00432-011-1061-6 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00432-011-1061-6 Verlag, Volltext: https://doi.org/10.1007/s00432-011-1061-6 
|
| Verfasserangaben: | Claus-Henning Köhne, Ralf Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Erick Gamelin, Lucy DeCosta, Meinolf Karthaus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580328490 | ||
| 003 | DE-627 | ||
| 005 | 20220814231454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180823r20122011xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00432-011-1061-6 |2 doi | |
| 035 | |a (DE-627)1580328490 | ||
| 035 | |a (DE-576)510328490 | ||
| 035 | |a (DE-599)BSZ510328490 | ||
| 035 | |a (OCoLC)1341017550 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Köhne, Claus-Henning |d 1959- |e VerfasserIn |0 (DE-588)122238206 |0 (DE-627)705825167 |0 (DE-576)293167060 |4 aut | |
| 245 | 1 | 0 | |a First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer |c Claus-Henning Köhne, Ralf Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Erick Gamelin, Lucy DeCosta, Meinolf Karthaus |
| 264 | 1 | |c 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First online: 30 September 2011 | ||
| 500 | |a Gesehen am 23.08.2018 | ||
| 520 | |a PurposePanitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated first-line panitumumab plus FOLFIRI in patients with mCRC.MethodsIn this phase II, single-arm study, panitumumab (6 mg/kg) and FOLFIRI [irinotecan (180 mg/m2) and leucovorin (400 mg/m2) followed by a 5-fluorouracil 400 mg/m2 bolus and a 2,400-3,000 mg/m2 continuous infusion] were administered every 14 days until progression. Data were analysed descriptively overall and by tumour KRAS status.Results KRAS data were available for 145/154 (94%) patients: 59% KRAS WT and 41% mutant (MT); mean follow-up was 39.5 versus 35.8 weeks, respectively. Objective responses occurred in 49% of patients: 56% versus 38% in the KRAS WT versus MT groups [(18% difference (95% CI 1-35%); odds ratio 2.1 (95% CI 1.0-4.4)]; median duration of response was 13.0 versus 7.4 months. More patients in the WT group underwent R0 resection (8% vs. 5%); median progression-free survival also favoured this group (8.9 vs. 7.2 months). The most common adverse events (any grade) were integument toxicities (98%), diarrhoea (79%) and stomatitis/oral mucositis (51%).ConclusionsAs expected, consistently favourable efficacy was observed in patients with KRAS WT versus MT tumours receiving first-line panitumumab plus FOLFIRI treatment. | ||
| 534 | |c 2011 | ||
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Fully human monoclonal antibody | |
| 650 | 4 | |a Metastatic colorectal cancer | |
| 650 | 4 | |a Panitumumab | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and clinical oncology |d Berlin : Springer, 1979 |g 138(2012), 1, Seite 65-72 |h Online-Ressource |w (DE-627)253769515 |w (DE-600)1459285-X |w (DE-576)072578319 |x 1432-1335 |7 nnas |a First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer |
| 773 | 1 | 8 | |g volume:138 |g year:2012 |g number:1 |g pages:65-72 |g extent:8 |a First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00432-011-1061-6 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00432-011-1061-6 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180823 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 999 | |a KXP-PPN1580328490 |e 3023010528 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title":"First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer","title_sort":"First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer"}],"name":{"displayForm":["Claus-Henning Köhne, Ralf Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Erick Gamelin, Lucy DeCosta, Meinolf Karthaus"]},"person":[{"given":"Claus-Henning","role":"aut","display":"Köhne, Claus-Henning","family":"Köhne"},{"family":"Hofheinz","display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1580328490","origin":[{"dateIssuedDisp":"2012","dateIssuedKey":"2012"}],"relHost":[{"titleAlt":[{"title":"Cancer research and clinical oncology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"253769515","origin":[{"publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"1979","dateIssuedDisp":"1979-","publisher":"Springer"}],"note":["Gesehen am 19.03.25","Teils ungezählte Beil.: Supplement"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancerJournal of cancer research and clinical oncology","id":{"eki":["253769515"],"zdb":["1459285-X"],"issn":["1432-1335"]},"part":{"issue":"1","extent":"8","pages":"65-72","volume":"138","year":"2012","text":"138(2012), 1, Seite 65-72"},"language":["eng","ger"],"title":[{"subtitle":"official organ of the Deutsche Krebsgesellschaft","title":"Journal of cancer research and clinical oncology","title_sort":"Journal of cancer research and clinical oncology"}],"pubHistory":["Volume 93, issue 1 (January 1979)-"]}],"note":["First online: 30 September 2011","Gesehen am 23.08.2018"],"physDesc":[{"extent":"8 S."}],"id":{"eki":["1580328490"],"doi":["10.1007/s00432-011-1061-6"]}} | ||
| SRT | |a KOEHNECLAUFIRSTLINEP2012 | ||